Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

It will be available at private hospitals as a booster dose for adults who have already been injected with 2 doses of either Covaxin or Covishield.

India nasal vaccine price: ₹800 at private, ₹325 in govt hospitals, GST extra for Bharat Biotech iNCOVACC

India nasal vaccine price revealed: ₹800 plus 5% GST for Bharat Biotech's iNCOVACC, says report | Covid


India nasal vaccine price revealed: ₹800 plus 5% GST for Bharat Biotech's iNCOVACC, says report

It will be available at private hospitals as a booster dose for adults who have already been injected with 2 doses of either Covaxin or Covishield.

Days after the Indian government cleared the use of the country's first nasal vaccine against Covid-19, the inoculant's price has been revealed.
Bharat Biotech's iNCOVACC is set to cost ₹800, excluding a Goods and Services Tax (GST) levy for private markets. The needle-less vaccine will cost ₹325 plus GST for government supplies.
A press release from the vaccine maker said the jab will be rolled out in the fourth week of January, 2023.
The approval of the nasal vaccine was announced on 23 December 2022. It will be available at private hospitals as a booster dose for adults who have already been injected with 2 doses of either Covaxin or Covishield.
The ministry's approval for the intranasal vaccine as a booster comes amid a spurt in Covid cases in China and some other countries.
The nasal vaccine -- BBV154 -- had received approval of the Drugs Controller General of India (DCGI) in November for restricted use in an emergency situation for those above 18 years as a heterologous booster dose.
The intranasal vaccine iNCOVACC is a recombinant replication deficient adenovirus vectored vaccine with a pre-fusion stabilised spike protein. This vaccine candidate was evaluated in phase I, II and III clinical trials with successful results, the Hyderabad-based vaccine-maker had said in a statement.
Clinical trials were conducted to evaluate iNCOVACC as a primary dose schedule as well as a heterologous booster dose for subjects who have previously received two doses of either Covishield or Covaxin.
(With PTI inputs)
Also Watch| <a href="https://www.editorji.com/coronavirus/china-becomes-first-to-roll-out-needle-free-covid-vaccine-which-is-inhaled-through-mouth-1666791059840">China becomes first to roll-out 'needle-free' Covid vaccine which is inhaled through mouth</a>

Bharat Biotech's iNCOVACC, the nasal vaccine recently approved by the Indian government, cannot be taken as a second booster dose.

Nasal vaccine not for those who've already taken booster dose: India vaccine task force head

Bharat Biotech's iNCOVACC, the nasal vaccine recently approved by the Indian government, cannot be taken as a second booster dose.

Bharat Biotech's iNCOVACC, the nasal vaccine recently approved by the Indian government, cannot be taken as a second booster dose, according to an NDTV report.
The needle-less vaccine is recommended as the first booster, and not meant for those who have already taken a precaution dose, the report quoted Dr NK Arora, head of India's vaccine task force, as saying.
He added that "at the moment", taking a fourth dose of vaccine is of "no value", and this option is also not available on the vaccination app CoWIN.
"Let us assume you want to take another fourth dose. There is a concept what is called as 'antigen sink'. If a person is repeatedly immunised with a particular type of antigen, the body stops responding, or responds poorly.
And that is why initially mRNA vaccines are given with a gap of six months. Later on, people are taking at three-month gap. But it has not helped too much in that case. Therefore, at the moment taking a fourth dose is of no value," Dr Arora said.
Also read|<a href="https://www.editorji.com/india-news/india-nasal-vaccine-price-revealed-800-plus-5-gst-for-bharat-biotech-s-incovacc-says-report-1672121485100">India nasal vaccine price: ₹800 at private, ₹325 in govt hospitals, GST extra for Bharat Biotech iNCOVACC</a>

incovacc

Categories